drugset / Trial / NCT01197144

Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab

NCT01197144

RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of this study is to obtain increased knowledge concerning central pain and fatigue processing in rheumatoid arthritis, and how these conditions are influenced by treatment with Tumor Necrosis Factor (TNF) blockade with adalimumab.

Timeline

Start
2010-10
Primary completion
2016-11-28
Completion
2016-11-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody 40 mg Subcutaneous

Indications